Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category


NIH SBIR Funding Early Ventures: September 26, 2018 sponsored by Pennovation

Stephen J. Williams PhD, Reporter

Penn Center for Innovation (Pennovation) sponsored a “Meet with NCI SBIR” program directors at University of Pennsylvania Medicine Smilow Center for Translational Research with a presentation on advice on preparing a successful SBIR/STTR application to the NCI as well as discussion of NCI SBIR current funding opportunities.   Time was allotted in the afternoon for one-on-one discussions with NCI SBIR program directors.

To find similar presentations and one-on-one discussions with NCI/SBIR program directors in an area nearest to you please go to their page at:

https://sbir.cancer.gov/newsevents/events

For more complete information on the NCI SBIR and STTR programs please go to their web page at: https://sbir.cancer.gov/about

A few notes from the meeting are given below:

  • In 2016 the SBIR/STTR 2016 funded $2.5 billion (US) of early stage companies; this is compared to the $6.6 billion invested in early  stage ventures by venture capital firms so the NCI program is very competitive with alternate sources of funding
  • It was stressed that the SBIR programs are flexible as far as ownership of a company; SBIR allows now that >50% of the sponsoring company can be owned by other ventures;  In addition they are looking more favorably on using outside contractors and giving leeway on budgetary constraints so AS THEY SUGGEST ALWAYS talk to the program director about any questions you may have well before (at least 1 month) you submit. More on eligibility criteria is found at: https://sbir.cancer.gov/about/eligibilitycriteria
  • STTR should have strong preliminary data since more competitive; if don’t have enough go for  an R21 emerging technologies grant which usually does not require preliminary data
  • For entities outside the US need a STRONG reason for needing to do work outside the US

Budget levels were discussed as well as  the waiver program, which allows for additional funds to be requested based on criteria set by NCI (usually for work that is deemed high priority or of a specialized nature which could not be covered sufficiently under the standard funding limits) as below:

Phase I: 150K standard but you can get waivers for certain work up to 300K

Phase II: 1M with waiver up to 2M

Phase IIB waiver up to 4M

You don’t need to apply for the waiver but grant offices may suggest citing a statement requesting a waiver as review panels will ask for this information

Fast Track was not discussed in the presentation but for more information of the Fast Track program please visit the website  

NCI is working hard to cut review times to 7 months between initial review to funding however at beginning of the year they set pay lines and hope to fund 50% of the well scored grants

NCI SBIR is a Centralized system with center director and then program director with specific areas of expertise: Reach out to them

IMAT Program and Low-Resource Setting new programs more suitable for initial studies and also can have non US entities

Phase IIB Bridge funding to cross “valley of death” providing up to 4M for 2-3 years: most were for drug/biological but good amount for device and diagnostics

 

Also they have announced administrative supplements for promoting diversity within a project: can add to the budget

FY18 Contracts Areas

3 on biotherapies

2 imaging related

2 on health IT

4 on radiation therapy related: NOTE They spent alot of time discussing the contracts centered on radiation therapy and seems to be an area of emphasis of the NCI SBIR program this year

4 other varied topics

 

Breakdown of funding

>70% of NCI SBIR budget went to grants (for instance Omnibus grants); about 20-30% for contracts; 16% for phase I and 34 % for phase II ;

ALSO the success rate considerably higher for companies that talk to the program director BEFORE applying than not talking to them; also contracts more successful than Omnibus applications

Take Advantage of these useful Assistance Programs through the NIH SBIR Program (Available to all SBIR grantees)

NICHE ASSESSMENT Program

From the NCI SBIR website:

The Niche Assessment Program is designed to help small businesses “jump start” their commercialization efforts. All active HHS (NIH, CDC, FDA) SBIR/STTR Phase I awardees and Phase I Fast-Track awardees (by grant or contract) are eligible to apply. Registration is on a first-come, first-serve basis!

The Niche Assessment Program provides market insight and data that can be used to help small businesses strategically position their technology in the marketplace. The results of this program can help small businesses develop their commercialization plans for their Phase II application, and be exposed to potential partners. Services are provided by Foresight Science & Technology of Providence, RI.

Technology Niche Analyses® (TNA®) are provided by Foresight, for one hundred and seventy-five (175), HHS SBIR/STTR Phase I awardees. These analyses assess potential applications for a technology and then for one viable application, it provides an assessment of the:

  1. Needs and concerns of end-users;
  2. Competing technologies and competing products;
  3. Competitive advantage of the SBIR/STTR-developed technology;
  4. Market size and potential market share (may include national and/or global markets);
  5. Barriers to market entry (may include but is not limited to pricing, competition, government regulations, manufacturing challenges, capital requirements, etc.);
  6. Market drivers;
  7. Status of market and industry trends;
  8. Potential customers, licensees, investors, or other commercialization partners; and,
  9. The price customers are likely to pay.

Commercialization Acceleration Program  (CAP)

From the NIH SBIR website:

NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in measurable gains and accomplishments by participating companies. Offered since 2004 to address the commercialization objectives of companies across the spectrum of experience and stage, 1000+ companies have participated in the CAP. It is open only to HHS/NIH SBIR/STTR Phase II awardees, and 80 slots are available each year. The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.

I-Corps Program

The I-Corps program provides funding, mentoring, and networking opportunities to help commercialize your promising biomedical technology. During this 8-week, hands-on program, you’ll learn how to focus your business plan and get the tools to bring your treatment to the patients who need it most.

Program benefits include:

  • Funding up to $50,000 to cover direct program costs
  • Training from biotech sector experts
  • Expanding your professional network
  • Building the confidence and skills to create a comprehensive business model
  • Gaining years of entrepreneurial skills in only weeks.

 

ICORPS is an Entrepreneurial Program (8 week course) to go out talk to customers, get assistance with business models, useful resource which can guide the new company where they should focus on for the commercialization aspect

THE NCI Applicant Assistance Program (AAP)

The SBIR/STTR Applicant Assistance Program (AAP) is aimed at helping eligible small R&D businesses and individuals successfully apply for Phase I SBIR/STTR funding from the National Cancer Institute (NCI), National Institute for Neurological Disorders and Stroke (NINDS), National Heart, Lung and Blood Institute (NHLBI). Participation in the AAP will be funded by the NCI, NINDS, and NHLBI with NO COST TO PARTICIPANTS. The program will include the following services:

  • Needs Assessment/Small Business Mentoring
  • Phase I Application Preparation Support
  • Application Review
  • Team/Facilities Development
  • Market Research
  • Intellectual Property Consultation

For more details about the program, please refer to NIH Notice NOT-CA-18-072.

 

These programs are free for first time grant applicants and must not have been awarded previous SBIR

Peer Learning Webinar Series goal to improve peer learning .Also they are starting to provide Regulatory Assistance (see below)

NIH also provides Mentoring programs for CEOS and C level

Application tips

  1. Start early: and obtain letters of collaboration
  2. Build a great team: PI multi PI, consider other partners to fill gaps (academic, consultants, seasoned entrepreneurs (don’t need to be paid)
  3. They will pre review 1 month before due date, use NIH Project Reporter to view previous funded grants
  4. Specify study section in SF to specify areas of expertise for review
  5. Specific aims are very important; some of the 20 reviewers focus on this page (describes goals and milestones as well; spend as much time on this page as the rest of the application
  6. Letters of support from KOLs are important to have; necessary from consultants and collaborators; helpful from clinicians
  7. Have a phase II commercialization plan
  8. Note for non US clinical trials:  They will not fund nonUS clinical trials; the company must have a FWA
  9. SBIR budgets defined by direct costs; can request a 7% fee as an indirect cost; and they have a 5,000 $ technical assistance program like regulatory consultants but if requested can’t participate in NIH technical assistance programs so most people don’t apply for TAP

 

  • They are trying to change the definition of innovation as also using innovative methods (previously reviewers liked tried and true methodology)

10.  before you submit solicit independent readers

NCI SBIR can be found on Twitter @NCIsbir ‏

Discussion with Monique Pond, Ph.D. on Establishment of a Regulatory Assistance Program for NCI SBIR

I was able to sit down with Dr. Monique Pond,  AAAS Science & Technology Policy Fellow, Health Scientist within the NCI SBIR Development Center to discuss the new assistance program in regulatory affairs she is developing for the NCI SBIR program.  Dr Pond had received her PhD in chemistry from the Pennsylvania State University, completed a postdoctoral fellow at NIST and then spent many years as a regulatory writer and consultant in the private sector.  She applied through the AAAS for this fellowship and will bring her experience and expertise in regulatory affairs from the private sector to the SBIR program. Dr. Pond discussed the difficulties that new ventures have in formulating regulatory procedures for their companies, the difficulties in getting face time with FDA regulators and helping young companies start thinking about regulatory issues such as pharmacovigilence, oversight, compliance, and navigating the complex regulatory landscape.

In addition Dr. Pond discussed the AAAS fellowship program and alternative career paths for PhD scientists.

 

A formal interview will follow on this same post.

 

Other articles on this OPEN ACCESS JOURNAL on Funding for Startups and Early Ventures are given below:

 

Mapping Medical Device Startups Across The Globe per Funding Criteria

Funding Oncorus’s Immunotherapy Platform: Next-generation Oncolytic Herpes Simplex Virus (oHSV) for Brain Cancer, Glioblastoma Multiforme (GBM)

 

Funding Opportunities for Cancer Research

 

Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator

 

A Message from Faculty Director Lee Fleming on Latest Issue of Crowdfunding; From the Fung Institute at Berkeley

 

PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

 

Foundations as a Funding Source

 

The Bioscience Crowdfunding Environment: The Bigger Better VC?

 

Advertisements

Read Full Post »


Cancer Cell Therapy: Global Start up Acquisitions in Oncolytic Viruses (OV) Therapeutics – a Pipeline of 70 OVs in Clinical Development and another 95 in Preclinical Programs

 

Reporter: Aviva Lev-Ari, PhD, RN

 

September 2018 

  • Boehringer Ingelheim is buying ViraTherapeutics in $244M deal

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal

https://endpts.com/boehringer-ingelheim-joins-the-crowd-and-goes-all-in-on-oncolytic-viruses-buying-viratherapeutics-in-244m-deal/?utm_medium=email&utm_campaign=Thursday%20September%2013%202018&utm_content=Thursday%20September%2013%202018+CID_61414a80a0003abe24ea7e26fafb3eab&utm_source=ENDPOINTS%20emails&utm_term=Boehringer%20Ingelheim%20joins%20the%20major%20league%20players%20with%20a%20buyout

 

May 2018

  • J&J executed one of its classic billion-dollar deals to buy BeneVir.

J&J’s Janssen to Acquire BeneVir for $1 Billion

May 09, 2018
By Pharmaceutical Technology Editors

Janssen Biotech, part of Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson (J&J), announced on May 2, 2018 that it has entered into a definitive agreement to acquire BeneVir Biopharm (BeneVir), a biotechnology company specializing in the development of oncolytic immunotherapies.

BeneVir is a portfolio company and subsidiary of HC2 Holdings’ Pansend Life Sciences, which is focused on developing healthcare technologies and products. Benevir uses a proprietary T-Stealth Oncolytic Virus Platform to engineer oncolytic viruses tailored to infect and eliminate cancer cells.

Under the terms of the agreement, Janssen will make an upfront cash payment of $140 million at closing of the transaction, plus additional contingent payments of up to $900 million based on achievement of certain predetermined milestones. The total amount of all payments could exceed $1 billion if all milestones are met. The closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction, which was facilitated by J&J Innovation, is expected to close in the second quarter of 2018.

SOURCE

http://www.pharmtech.com/jj-s-janssen-acquire-benevir-1-billion-0

 

May 2018

  • A recent study from the Cancer Research Institute found 69 OVs in clinical development and another 95 in a preclinical program.

New Report on the Global Landscape of Cancer Cell Therapy Highlights Robust International Pipeline Marked by Rapid Growth

  • A comprehensive, neutral analysis of the global cancer cell therapy landscape
  • 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
  • 350 new cancer cell therapies have entered the global development pipeline since Sep. 2017, an 87% increase in less than 7 months
  • 113 targets are being pursued in 7 different classes of cell therapies

NEW YORK, May 25, 2018—The Cancer Research Institute (CRI) announced today the publication of a report that provides a comprehensive, independent analysis of the global landscape of cancer cell therapies, including all agents from preclinical to post-market stages. This report provides a quantitative and current overview of the cancer cell therapy field, reveals the unparalleled speed of the field’s expansion, highlights exciting innovations in the development pipeline, and advises strategies to advance the field as a whole.

The report, titled “The Global Landscape of Cancer Cell Therapy,” appeared online today in Nature Reviews Drug Discovery, a premium journal from Nature Publishing Group and an authoritative source of information in drug discovery and development. This report, which expands on CRI’s previously published landscape analysis of the entire field of immuno-oncology, highlights the geographic distribution of cancer cell therapies worldwide and identifies the dominant presence of CAR T therapies in the cancer cell therapy space.

“The quantitative analyses from this report reveal unprecedented enthusiasm and innovation in the global cell therapy pipeline,” said Jill O’Donnell-Tormey, Ph.D., chief executive officer and director of scientific affairs at the Cancer Research Institute.

“In addition to traditional powerhouses of drug development such as the United States or European countries, many other countries, especially China, have significant presence in this space,” noted Jun Tang, Ph.D., a senior research analyst for the CRI Anna-Maria Kellen Clinical Accelerator program and first author on the report.

To access the interactive dashboard of the report, visit the CRI website at cancerresearch.org/io-cell-therapy.

Reference
Tang J. et al. Global landscape of cancer cell therapy. Nature Reviews Drug Discovery. 25 May 2018. doi:10.1038/nrd.2018.74

SOURCE

https://www.cancerresearch.org/news/2018/global-landscape-of-cancer-cell-therapy-report

 

February 2018

  • Merck’s R&D chief Roger Perlmutter — who steered the T-Vec deal at Amgen — bagged Viralytics for $394 million.
FEBRUARY 21, 2018 / 4:29 AM / 7 MONTHS AGO

Merck to buy virus-based cancer drug firm Viralytics for $394 million

(Reuters) – U.S. drugmaker Merck & Co (MRK.N), already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics VLA.AX for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.

Merck will pay 1.75 Australian dollars per share for the Sydney-based biotech company, which uses viruses to infect and kill cancer cells.

The idea is to cause cancer cells to rupture and die, while also stimulating a wider immune system response in the body.

SOURCE

https://www.reuters.com/article/us-viralytics-m-a-merck-co/merck-to-buy-virus-based-cancer-drug-firm-viralytics-for-394-million-idUSKCN1G50ZN

 

Hum Vaccin Immunother. 2018; 14(4): 839–846.
Published online 2018 Feb 22. doi:  10.1080/21645515.2017.1412896
PMCID: PMC5893211
PMID: 29420123

Talimogene laherparepvec: First in class oncolytic virotherapy

ABSTRACT

Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC’s biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.

SOURCE

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893211/

October 2015 

  • Amgen’s landmark approval of T-Vec, the world’s first marketed oncolytic virus.

FDA approves cancer-killing cold sore virus as therapy for late-stage melanoma

October 28, 2015, University of Utah Health Sciences
melanoma
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

The approval came as the result of a recent Phase III study, which showed that more patients with late-stage melanoma, treated with a herpes cold sore virus designed to kill , had a better response when compared to a different treatment. Robert Andtbacka, M.D., from Huntsman Cancer Institute at the University of Utah and Howard L. Kaufman, M.D., from Rutgers Cancer Institute of New Jersey, led the multisite study, published May 26 online in the Journal of Clinical Oncology.

SOURCE

https://medicalxpress.com/news/2015-10-fda-cancer-killing-cold-sore-virus.html

 

Additional Sources

T Cell Engineering Breakthrough Sidesteps Need for Viruses in Gene-Editing
UCSF News Center | Pete Farley | July 11, 2018

With Faster, Cheaper, More Precise Technique, Authors Say It’s ‘Off to the Races’ Toward New Cell

The basic unit of life. The number of cells in a living organism ranges from one (e.g. yeast) to quadrillions (e.g. blue whale). A cell is composed of four key macromolecules that allow it to function (protein, lipids, carbohydrates, and nucleic acids). Among other things, cells can build and break down molecules, move, grow, divide, and die.

” aria-describedby=”tt”>CellTherapies

In an achievement that has significant implications for research, medicine, and industry, UC San Francisco scientists have genetically reprogrammed the human immune cells known as T cells without using Virus

An infectious entity that can only persist by hijacking a host organism to replicate itself. Has its own genome, but is technically not considered a living organism. Viruses infect all organisms, from humans to plants to microbes. Multicellular organisms have sophisticated immune systems that combat viruses, while CRISPR systems evolved to stop viral infection in bacteria and archaea.

” aria-describedby=”tt”>viruses to insert DNA

Abbreviation of deoxyribonucleic acid, a long molecule that encodes the information needed for a cell to function or a virus to replicate. Forms a double-helix shape that resembles a twisted ladder. Different chemicals called bases, abbreviated as A, C, T, and G, are found on each side of the ladder, or strand. The bases have an attraction for each other, making A stick to T while C sticks to G. These rungs of the ladder are called base pairs. The sequence of these letters is called the genetic code.

” aria-describedby=”tt”>DNA. The researchers said they expect their technique — a rapid, versatile, and economical approach employing CRISPR

Pronounced “crisper.” An adaptive immune system found in bacteria and archaea, co-opted as a genome engineering tool. Acronym of “clustered regularly interspaced short palindromic repeats,” which refers to a section of the host genome containing alternating repetitive sequences and unique snippets of foreign DNA. CRISPR-associated surveillance proteins use these unique sequences as molecular mugshots as they seek out and destroy viral DNA to protect the cell.

” aria-describedby=”tt”>CRISPR Gene

A segment of DNA that encodes the information used to make a protein. Each gene is a set of instructions for making a particular molecular machine that helps a cell, organism, or virus function.

” aria-describedby=”tt”>gene-editing technology — to be widely adopted in the burgeoning field of cell therapy, accelerating the development of new and safer treatments for Cancer

A type of disease caused by uncontrolled growth of cells. Cancerous cells may form clumps or masses known as tumors, and can spread to other parts of the body through a process known as metastasis.

” aria-describedby=”tt”>cancer, autoimmunity, and other diseases, including rare inherited disorders.

The new method, described in the July 11, 2018 issue of Nature, offers a robust molecular “cut and paste” system to rewrite Genome

The entire DNA sequence of an organism or virus. The genome is essentially a huge set of instructions for making individual parts of a cell and directing how everything should run.

” aria-describedby=”tt”>genome sequences in human T cells. It relies on electroporation, a process in which an electrical field is applied to cells to make their membranes temporarily more permeable. After experimenting with thousands of variables over the course of a year, the UCSF researchers found that when certain quantities of T cells, DNA, and the CRISPR “scissors” are mixed together and then exposed to an appropriate electrical field, the T cells will take in these elements and integrate specified genetic sequences precisely at the site of a CRISPR-programmed cut in the genome.

“This is a rapid, flexible method that can be used to alter, enhance, and reprogram T cells so we can give them the specificity we want to destroy cancer, recognize infections, or tamp down the excessive immune response seen in autoimmune disease,” said UCSF’s Alex Marson, MD, PhD, associate professor of microbiology and immunology, member of the UCSF Helen Diller Family Comprehensive Cancer Center, and senior author of the new study. “Now we’re off to the races on all these fronts.”

But just as important as the new technique’s speed and ease of use, said Marson, also scientific director of biomedicine at the Innovative Genomics

The study of the genome, all the DNA from a given organism. Involves a genome’s DNA sequence, organization and control of genes, molecules that interact with DNA, and how these different components affect the growth and function of cells.

” aria-describedby=”tt”>Genomics Institute, is that the approach makes it possible to insert substantial stretches of DNA into T cells, which can endow the cells with powerful new properties. Members of Marson’s lab have had some success using electroporation and CRISPR to insert bits of genetic material into T cells, but until now, numerous attempts by many researchers to place long sequences of DNA into T cells had caused the cells to die, leading most to believe that large DNA sequences are excessively toxic to T cells.

SOURCE

https://innovativegenomics.org/news/t-cell-engineering-breakthrough-sidesteps-viruses/

 

Cancer Res. 2016 Aug 15; 76(16): 4627–4636.

Published online 2016 Jun 3. doi:  10.1158/0008-5472.CAN-15-3455

PMCID: PMC5295843

CAMSID: CAMS5780

PMID: 27261504

Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy

James Mattina,1 Nathalie MacKinnon,1 Valerie C. Henderson,1 Dean Fergusson,2 andJonathan Kimmelman

 

Other 17 related articles published in this Online Scientific Journal include the following:

https://pharmaceuticalintelligence.com/category/oncolytic-virus-oncoviro-therapy/

Read Full Post »

Entrepreneurship in Biotech – Read this book!!!


Entrepreneurship in Biotech – Read this book!!!

Reporter: Aviva Lev-Ari, PhD, RN

 

ARE YOU INTERESTED IN #Entrepreneurship in Biotech??? – Read this book!!!

Hammer and Silicon: The Soviet Diaspora in the US Innovation Economy – Immigration, Innovation, Institutions, Imprinting, and Identity

by Sheila M. Puffer (Author), Daniel J. McCarthy  (Author), Daniel M. Satinsky  (Author)

Paperback – June 30, 2018

https://www.amazon.com/Hammer-Silicon-Innovation-Immigration-Institutions/dp/1316641260/ref=sr_1_1?s=books&ie=UTF8&qid=1536715051&sr=1-1&keywords=Hammer+and+SIlicon

Read Full Post »

Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018


Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018

Curator: Aviva Lev-Ari, PhD, RN

 

Please review:

https://pharmaceuticalintelligence.com/2018/06/11/re-tweets-and-likes-by-pharma_bi-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

 

https://pharmaceuticalintelligence.com/2018/06/11/original-tweets-by-pharma_bi-and-by-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

 

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

 

     liked a Tweet you were mentioned in

    4h4 hours ago

  1. Gail Thornton Retweeted @pharma_BI

    From Philip K Dick’s obtuse robots to Mark O’Connell’s guide to transhumanism, novelist Julian Gough picks essential reading for a helter skelter world. Can’t wait to read some of the top 10 books. to survive the digital age!

    Gail Thornton added,

     liked your Tweet

    Jun 8

    In case you missed Gail Thornton‘s Tweet

    Jun 8

  2. Gail Thornton Retweeted Aviva Lev-Ari

    Gail Thornton added,

     Retweeted your Tweet

    Jun 8

  3.  liked your Tweets

    Jun 8

    3 other likes

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

     Retweeted your Tweet

    Jun 7

     liked your Tweet

    Jun 7

  4. Replying to  

    Thanks to Pete Pellerito for keeping the academic zone going . It was great.

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

  5. Replying to   and 2 others

    👊👏🙏

     liked your reply

    Jun 7

     liked your Retweet

    Jun 7

  6.  Retweeted your Retweets

    Jun 6

    10 other Retweets

     Retweeted a Tweet you are mentioned in

    Jun 6

  7.  liked your Tweets

    Jun 6

    2 other likes

  8.  Retweeted your Tweet

    Jun 6

    1 other Retweet

     Retweeted your Tweet

    Jun 6

  9.  liked your Retweets

    Jun 6

    2 other likes

     Retweeted your Retweet

    Jun 6

     and  liked your Tweet

    Jun 6

     and  liked your Tweet

    Jun 6

     and  liked your Tweet

    Jun 6

     liked your Tweet

    Jun 6

     Retweeted your Tweet

    Jun 6

     liked your Tweet

    Jun 6

     liked your Tweet

    Jun 5

     and  liked a Tweet you were mentioned in

    Jun 5

    Recent Tweet from Gail Thornton

    Jun 5

  10. Translate Tweet

  11.  liked Tweets you were included in

    Jun 5

    1 other like

  12.  liked your Tweets

    Jun 5

    7 other likes

     liked your Tweet

    Jun 5

     Retweeted your Tweet

    Jun 4

     Retweeted your reply

    Jun 4

     liked your reply

    Jun 4

     liked your reply

    Jun 4

     liked your reply

    Jun 4

  13.  liked your Tweets

    Jun 4

    1 other like

     liked your Tweet

    Jun 3

Read Full Post »

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL


Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Author and Curator: Aviva Lev-Ari, PhD, RN

 

The source for the inspiration to write this curation is described in

Survival Calls during Careers in the Digital Age

https://pharmaceuticalintelligence.com/2018/06/13/survival-calls-during-careers-in-the-digital-age/

 

In this curation, I present the following concepts in three parts:

  1. Part 1: Authenticity of Careers in the Digital Age: In Focus, the BioTechnology Sector
  2. Part 2: Top 10 books to help you survive the Digital Age

  3. Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76 

 

Part 1: Authenticity of Careers in the Digital Age: 

In Focus, the BioTechnology Sector

 

Lisa LaMotta, Senior Editor, BioPharma Dive wrote in Conference edition | June 11, 2018

Unlike that little cancer conference in Chicago last week, the BIO International convention is not about data, but about the people who make up the biopharma industry.

The meeting brings together scientists, board members, business development heads and salespeople, from the smallest virtual biotechs to the largest of pharmas. It allows executives at fledgling biotechs to sit at the same tables as major decision-makers in the industry — even if it does look a little bit like speed dating.

But it’s not just a partnering meeting.

This year’s BIO also sought to shine a light on pressing issues facing the industry. Among those tackled included elevating the discussion on gender diversity and how to bring more women to the board level; raising awareness around suicide and the need for more mental health treatments; giving a voice to patient advocacy groups; and highlighting the need for access to treatments in developing nations.

Four days of meetings and panel discussions are unlikely to move the needle for many of these challenges, but debate can be the first step toward progress.

I attended the meetings on June 4,5,6, 2018 and covered in Real Time the sessions I attended. On the link below, Tweets, Re-Tweets and Likes mirrors the feelings and the opinions of the attendees as expressed in real time using the Twitter.com platform. This BioTechnology events manifested the AUTHENTICITY of Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL.

The entire event is covered on twitter.com by the following hash tag and two handles:

 

I covered the events on two tracks via two Twitter handles, each handle has its own followers:

The official LPBI Group Twitter.com account

The Aviva Lev-Ari, PhD, RN Twitter.com account

Track A:

  • Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/original-tweets-by-pharma_bi-and-by-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

 

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/12/reactions-to-original-tweets-by-pharma_bi-and-by-aviva1950-from-bio2018/

Track B:

  • Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/re-tweets-and-likes-by-pharma_bi-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

Part 2: Top 10 books to help you survive the digital age

From Philip K Dick’s obtuse robots to Mark O’Connell’s guide to transhumanism, novelist Julian Gough picks essential reading for a helter skelter world

Here are 10 of the books that did help me [novelist Julian Gough]: they might also help you understand, and survive, our complicated, stressful, digital age.

  1. Marshall McLuhan Unbound by Marshall McLuhan (2005)
    The visionary Canadian media analyst predicted the internet, and coined the phrase the Global Village, in the early 1960s. His dense, complex, intriguing books explore how changes in technology change us. This book presents his most important essays as 20 slim pamphlets in a handsome, profoundly physical, defiantly non-digital slipcase.
  2. Ubik by Philip K Dick (1969)
    Pure pulp SF pleasure; a deep book disguised as a dumb one. Dick shows us, not a dystopia, but a believably shabby, amusingly human future. The everyman hero, Joe Chip, wakes up and argues with his robot toaster, which refuses to toast until he sticks a coin in the slot. Joe can’t do this, because he’s broke. He then has a stand-up row with his robot front door, which won’t open, because he owes it money too … Technology changes: being human, and broke, doesn’t. Warning: Dick wrote Ubik at speed, on speed. But embedded in the pulpy prose are diamonds of imagery that will stay with you for ever.
  3. The Singularity Is Near by Ray Kurzweil (2005)
    This book is what Silicon Valley has instead of a bible. It’s a visionary work that predicts a technological transformation of the world in our lifetime. Kurzweil argues that computer intelligence will soon outperform human thought. We will then encode our minds, upload them, and become one with our technology, achieving the Singularity. At which point, the curve of technological progress starts to go straight up. Ultimately – omnipotent, no longer mortal, no longer flesh – we transform all the matter in the universe into consciousness; into us.
  4. To Be a Machine by Mark O’Connell (2017)
    This response to Kurzweil won this year’s Wellcome prize. It’s a short, punchy tour of transhumanism: the attempt to meld our minds with machines, to transcend biology and escape death. He meets some of the main players, and many on the fringes, and listens to them, quizzically. It is a deliberately, defiantly human book, operating in that very modern zone between sarcasm and irony, where humans thrive and computers crash.
  5. A Visit from the Goon Squad by Jennifer Egan (2011)
    This intricately structured, incredibly clever novel moves from the 60s right through to a future maybe 15 years from now. It steps so lightly into that future you hardly notice the transition. It has sex and drugs and rock’n’roll, solar farms, social media scams and a stunningly moving chapter written as a PowerPoint presentation. It’s a masterpiece. Life will be like this.
  6. What Technology Wants by Kevin Kelly (2010)
    Kelly argues that we scruffy biological humans are no longer driving technological progress. Instead, the technium, “the greater, global, massively interconnected system of technology vibrating around us”, is now driving its own progress, faster and faster, and we are just caught up in its slipstream. As we accelerate down the technological waterslide, there is no stopping now … Kelly’s vision of the future is scary, but it’s fun, and there is still a place for us in it.
  7. The Meme Machine by Susan Blackmore (1999)
    Blackmore expands powerfully and convincingly on Richard Dawkins’s original concept of the meme. She makes a forceful case that technology, religion, fashion, art and even our personalities are made of memes – ideas that replicate, mutate and thus evolve over time. We are their replicators (if you buy my novel, you’ve replicated its memes); but memes drive our behaviour just as we drive theirs. It’s a fascinating book that will flip your world upside down.
  8. Neuromancer by William Gibson (1984)
    In the early 1980s, Gibson watched kids leaning into the screens as they played arcade games. They wanted to be inside the machines, he realised, and they preferred the games to reality. In this novel, Gibson invented the term cyberspace; sparked the cyberpunk movement (to his chagrin); and vividly imagined the jittery, multi-screened, anxious, technological reality that his book would help call into being.
  9. You Are Not a Gadget: A Manifesto by Jaron Lanier (2010)
    Lanier, an intense, brilliant, dreadlocked artist, musician and computer scientist, helped to develop virtual reality. His influential essay Digital Maoism described early the downsides of online collective action. And he is deeply aware that design choices made by (mainly white, young, male) software engineers can shape human behaviour globally. He argues, urgently, that we need to question those choices, now, because once they are locked in, all of humanity must move along those tracks, and we may not like where they take us. Events since 2010 have proved him right. His manifesto is a passionate argument in favour of the individual voice, the individual gesture.
  10. All About Love: New Visions by bell hooks (2000)
    Not, perhaps, an immediately obvious influence on a near-future techno-thriller in which military drones chase a woman and her son through Las Vegas. But hooks’s magnificent exploration and celebration of love, first published 18 years ago, will be far more useful to us, in our alienated digital future, than the 10,000 books of technobabble published this year. All About Love is an intensely practical roadmap, from where we are now to where we could be. When Naomi and Colt find themselves on the run through a militarised American wilderness of spirit, when GPS fails them, bell hooks is their secret guide.

SOURCE

https://www.theguardian.com/books/2018/may/30/top-10-books-to-help-you-survive-the-digital-age?utm_source=esp&utm_medium=Email&utm_campaign=Bookmarks+-+Collections+2017&utm_term=277690&subid=25658468&CMP=bookmarks_collection

Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age:  Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76

 

On June 10, 2018

 

Following, is a case study about an alumna of HUJI and UC, Berkeley as an inspirational role model. An alumna’s profile in context of dynamic careers in the digital age. It has great timeliness and relevance to graduate students, PhD level at UC Berkeley and beyond, to all other top tier universities in the US and Europe. As presented in the following curations:

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

https://pharmaceuticalintelligence.com/2018/05/22/professional-self-re-invention-from-academia-to-industry-opportunities-for-phds-in-the-business-sector-of-the-economy/

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76 

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

 

This alumna is Editor-in-Chief of a Journal that has other 173 articles on Scientist: Career Considerations 

https://pharmaceuticalintelligence.com/category/scientist-career-considerations/

 

In a 5/22/2018 article, Ways to Pursue Science Careers in Business After a PhD by Ankita Gurao,

https://bitesizebio.com/38498/ways-to-pursue-the-business-of-science-after-a-ph-d/?utm_source=facebook&utm_medium=social&utm_campaign=SocialWarfare

Unemployment figures of PhDs by field of science are included, Ankita Gurao identifies the following four alternative careers for PhDs in the non-academic world:

  1. Science Writer/Journalist/Communicator
  2. Science Management
  3. Science Administration
  4. Science Entrepreneurship

My career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

has the following phases:

These four phases are easily mapped to the four alternative careers for PhDs in the non-academic world. One can draw parallel lines between the four career opportunities A,B,C,D, above, and each one of the four phases in my own career.

Namely, I have identified A,B,C,D as early as 1985, and pursued each of them in several institutional settings, as follows:

A. Science Writer/Journalist/Communicator – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present 

B. Science Management – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005 and Phase 3: Career Reinvention in Health Care, 2005 – 2012 

C. Science Administration – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005and Phase 4: Electronic Scientific Publishing, 4/2012 to present 

D. Science Entrepreneurship – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present  

Impressions of My Days at Berkeley in Recollections: Part 1 and 2, below.

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

The topic of Careers in the Digital Age is closely related to my profile, see chiefly: Four-phase Career, Reflections, Recollections Parts 1 & 2 and information from other biographical sources, below.

Other sources for my biography

 

Read Full Post »

Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC


  1. ⁩ ⁦⁩ in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement text mining sensation reported by patients with sensors trajectory monitored drug device external partnership

  2. ⁩ ⁦ new drug: Biotech in Scripps, CA and another in Cambridge, MA and ⁦⁩ as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma

  3. ⁩ ⁦ and Medical community decide on directions for surrogate followed by survival NASH redefine NEW drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration

  4. ⁩ immunicity correlated confirm benefit in based study patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient

  5. ⁩ ⁦⁩ redefine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection

  6. Mikael Dolsten R&D budget for contribution capital allocation focus on deep expertise in multiple drugs in multiple indications Lipitor dependence ends patent expiration

  7. only by knowing both one can develop applications in vs questions are the hard part vs expertise needed for structural models type of data collected may not be best

  8. for idiopathic fibrosis using CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug

  9. for patients goals apply right approach to care right drug respond to therapy is a HC goal combined with patient goals

  10. @FoundationMedicine in 7 days genomic data, clinical data and patient of patient took place in clean data sets are a must for patient total clinical profile

  11. COHORT is assisted by for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for can get wrong results by using

  12. @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials. use of on genomic data for

  13. @KatrineBosley @EditasMedicine Valuation for 23andme? Each pool of capital has different investors been attracted

  14. @JohnMaraganore @ALNYLAMPHARMACEUTICALS In 16 years rained $4Billion and expenses $2.5Billion – still not profitable – that what it takes

  15. @JeanFrancisFormela Science is extraordinary A lot of capital and very many tech ventures over supply of capital accelerates the business More capital is better, what to invest is critical

  16. US is not the only player, CANADA’ universal payer system made major strides lung cancer experienced development of 50 drug base on tumor type predict likelihood drug resistance BR CA patient which not require therapy

  17. @RajuKucherlapati Integration of EMR Partners leader missing link is integration of Genomic dat aat the patient level with clinical dat of patients Patients will manage their 23andme data PM is global vs access to care

  18. @RajuKucherlapati with million of people with genetic and medical information — searches of profile too group patients for optimal of with DB of – IBM

  19. @RajuKucherlapati Detection at pre-natal stages of multiple fetal disorders, abnormality, diagnosis drive treatment – genetic testing critical in cost Cardiomayopaty: in Young athlete genetic disorder

  20. Sajeev Kohli (11th Grade, Waterloo, On, Canada)Receives Top Honor at International BioGENEius Challenge Students from California, Washington and Germany named runners-up June 5, 2018 – Boston, Massachusetts –

  21. @TimothyBelski Joint Program Executive Office for Chemical and Biological Defense Manufacturing for DoD Infrastructure to manage across Government RFP Process

  22. We cover this event in Real Time

  23. Aviva Lev-Ari Retweeted MassBio

    BRAVO MA the of

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted JNJ Innovation

    Interested Chief Scientific Officer

    Aviva Lev-Ari added,

Read Full Post »

Re-Tweets and Likes by @Pharma_BI @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC


Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

 

  1.   Retweeted

    Aviva Lev-Ari Retweeted Jeff Galvin

    Well put I agree with you, Jeff

    Aviva Lev-Ari added,

  2.   Retweeted

    Aviva Lev-Ari Retweeted I Am Biotech

    Aviva Lev-Ari added,

  3. Aviva Lev-Ari Retweeted Christiane Truelove

    BRAVO FDA in 2018 is AGILE

    Aviva Lev-Ari added,

  4. Aviva Lev-Ari Retweeted CCAB

    ASCO weigh in on CAR-Ts versus bispecific antibodies

    Aviva Lev-Ari added,

  5. Aviva Lev-Ari Retweeted Dana-Farber News

    Aviva Lev-Ari added,

  6. Aviva Lev-Ari Retweeted Jim Greenwood

    BRAVO inaugural Henri A. Termeer Biotechnology Visionary Award

    Aviva Lev-Ari added,

  7. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  8.   Retweeted

    The 2018 Bio International Convention has been amazing! This was the view from our water taxi ride to the hotel last night! 🚤🛳🛥⛵️

  9. Aviva Lev-Ari Retweeted Ozmosi

    Aviva Lev-Ari added,

  10. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi

    Aviva Lev-Ari added,

  11. Aviva Lev-Ari Retweeted Sue Desmond-Hellmann

    HEROS for cure

    Aviva Lev-Ari added,

  12. Aviva Lev-Ari Retweeted BIO Intl Convention

    Aviva Lev-Ari added,

  13. Aviva Lev-Ari Retweeted Noy Kaufman

    Aviva Lev-Ari added,

  14. Aviva Lev-Ari Retweeted Business Sweden Invest

    Aviva Lev-Ari added,

  15. Aviva Lev-Ari Retweeted Alaric DeArment

    Aviva Lev-Ari added,

  16. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  17. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  18. Aviva Lev-Ari Retweeted Elizabeth Cutler

    Aviva Lev-Ari added,

  19. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi, so smart to have bought Genzyme

    Aviva Lev-Ari added,

  20. Aviva Lev-Ari Retweeted Biotech Institute

    BRAVO Challenge!

    Aviva Lev-Ari added,

  21. Aviva Lev-Ari Retweeted IAM Platform

    Aviva Lev-Ari added,

  22. Aviva Lev-Ari Retweeted Sema4

    Aviva Lev-Ari added,

  23. Aviva Lev-Ari Retweeted Worldwide Clinical

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted Lori Collins

    ‘Largest Business Partnering Event’! Proud to cover the event in

    Aviva Lev-Ari added,

  25. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  26. Aviva Lev-Ari Retweeted Cleveland Scott York

    45,000 Partening sessions – BRAVO !!

    Aviva Lev-Ari added,

  27. Aviva Lev-Ari Retweeted Thermo Fisher G.R.

    Aviva Lev-Ari added,

  28. Aviva Lev-Ari Retweeted The Global IP Center

    Aviva Lev-Ari added,

  29. Aviva Lev-Ari Retweeted NHS Research Scotland

    BRAVO Scotland in

    Aviva Lev-Ari added,

  30. Aviva Lev-Ari Retweeted Quanterix

    BRAVO landscape in in light of

    Aviva Lev-Ari added,

  31. Aviva Lev-Ari Retweeted Vanitha Sekar

    made by Bill & Melinda Gates Medical Research Institution most nobel cause

    Aviva Lev-Ari added,

  32. Aviva Lev-Ari Retweeted HLC

    in Medicine

    Aviva Lev-Ari added,

  33. Aviva Lev-Ari Retweeted BlueCloud

    BRAVO Argentine

    Aviva Lev-Ari added,

  34. Aviva Lev-Ari Retweeted NFIA North America

    BRAVO Holland! places Holland No. 1 in the world for medical technology patents!

    Aviva Lev-Ari added,

  35. Aviva Lev-Ari Retweeted Intract Pharma

    Amazing COnference

    Aviva Lev-Ari added,

  36. Aviva Lev-Ari Retweeted MacBioCom

    Aviva Lev-Ari added,

  37. Aviva Lev-Ari Retweeted Hassan Naqvi

    meets INDUSTRY: BIOTECH & PHARMA with success

    Aviva Lev-Ari added,

  38. Aviva Lev-Ari Retweeted IN-PART

    INDEED, the best conference I have attended since 2013 when I cover in Real Time conferences as

    Aviva Lev-Ari added,

  39. Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO J&J for your broad spectrum in

    Aviva Lev-Ari added,

  40. Aviva Lev-Ari Retweeted Penny Heaton

    MOST NOBEL cause by MRI can be a catalyst to address urgent global health

    Aviva Lev-Ari added,

  41. Aviva Lev-Ari Retweeted I Am Biotech

    bRAVO I Am Biotech

    Aviva Lev-Ari added,

  42. Aviva Lev-Ari Retweeted ARMI

    BRAVO Aussi

    Aviva Lev-Ari added,

  43.   Retweeted

    Fireside chat with at

  44.   Retweeted

    Jeff Galvin, CEO of Rockville-based presented his company’s innovations in therapies for HIV, phenylketonuria, and cancer at . After the presentation, he was mobbed by potential investors and partners!

  45.   Retweeted

    How do you schedule hundreds of meetings all at once? has it figured out. Meeting many great potential supporters.

  46.   Retweeted

    It doesn’t get more epic than this l! The QUEEN, DIANA ROSS!

  47.   Retweeted

    Absolutely inspiring group of advocates on the patient voice panel. I feel honored to be in the room with them, listening to their remarkable stories and insights.

  48.   Retweeted

    Board of Directors Chair on diversity in during his Fireside Chat

  49.   Retweeted

    And for more on-the-ground analysis while you’re at , sign up for our daily newsletter, BIO in 30 Seconds.

  50.   Retweeted

    THURSDAY: (yes, twice!), 9:00am, 259B, on biotech’s data tsunami

  51.   Retweeted

    TUESDAY: , 4:15pm, 259A, on a new era of biotech journalism

  52.   Retweeted

    TUESDAY: , 1:45pm, 210B, on how to apply the lessons of immunotherapy from cancer to other diseases.

  53.   Retweeted

    MONDAY: , 4:00pm, 210A, talking how to cut waste between big pharma and payers in precision medicine.

  54.   Retweeted

    MONDAY: , 1:00pm, 206AB, talking what drug hunters look for in early stage assets.

  55.   Retweeted

    MONDAY: , 12:30pm at , talking best practices for co-working in the life sciences. (From the archives)

  56.   Retweeted

    THREAD: STAT is all over . Here’s where to find us.

  57.   Retweeted

    speaking with the member delegation at We’ve come to share with the world the excellence of our life science community in Canada.

  58.   Retweeted

    Team Queensland ready to showcase our state’s fantastic capabilities in all things biotech in Boston

  59.   Retweeted

    kicks off tomorrow in Boston, MA. Dr Glenn Begley, CEO and Linda Peterson, COO will be attending. DM us if you would like to connect with them.

  60.   Retweeted

    Heading to my first BIO convention, the rain can’t stop my excitement! 😁

  61.   Retweeted

    Proud to sponsor . We at love supporting and their missions to improve our health! See you at as we keep the startup celebration going tomorrow night! BIOGA25 for $25 GA tix

  62.   Retweeted

    Our friends at have put together the ultimate guide to the (). It features a complete list of conferences, private events/receptions, plus much more, all happening throughout the week. Get it here >>

  63.   Retweeted

    Through Pfizer Ventures, we plan to invest $600M in innovative science, with approximately $150M specifically targeted toward neuroscience. Join us at to learn more:

  64.   Retweeted

    “It will take you 10-15 years to get a breakthrough, but if you don’t start, you’ll never get there,” says J&J’s CSO Paul Stoffels when asked about at – at Boston Convention & Exhibition Center

  65.   Retweeted
  66.   Retweeted

    Great Q on driving (innovation in) “Huge opportunity in partnering with Pharma, not in replacing them, mainly due to the complexity of

  67.   Retweeted

    Penny Heaton Retweeted BIO Intl Convention

    Looking forward to next week, where we’ll have the opportunity to formally introduce the Gates MRI and share the mission, vision, and values behind the work we’re doing to accelerate product development for diseases that disproportionately affect the world’s poorest.

    Penny Heaton added,

  68.   Retweeted

    Attending ? These SECRET STAIRS, only minutes from the convention center, lead to our local Fort Point restos, breweries and more!

  69.   Retweeted

    At … it’s like Epcot in here! So many countries and states courting the bio biz.

  70.   Retweeted

    the best way to conclude this incredible !!!

  71.   Retweeted

    Making History in Boston.

  72.   Retweeted

    At biggest biopharma partnering event in the world, scale is pretty amazing…

  73.   Retweeted

    I can’t believe attendees are told by conference organizers that “locals” recommend: “Let loose and explore the nightlife of Boston, grab a couple beers at the iconic “Cheers” bar.” Let me qualify that: NOBODY IN THIS CITY WOULD RECOMMEND THAT.

  74.   Retweeted

    How cool is this new tool from ?! It provides info on partnering opportunities and contacts for over 60+ patient advocacy groups. Very useful!

  75.   Retweeted

    And here it is, the most famous Paul Stoffels quote we hear ALL THE TIME at “You take the risk and I take the blame” in

  76.   Retweeted

    We MADE GUINNESS HISTORY!

  77.   Retweeted

    . – tonight, Karl-Rudolf Erlemann of was all of us.

  78.   Retweeted

    Which biopharmaceutical companies are making a real difference for patients? Our CSO Michael Severino explains how to spot R&D leaders.

  79.   Retweeted

    Had to get to the front row for the encore at live!

  80.   Retweeted

    There is till time to visit us at , booth 1344. If you require nucleosides and carbohydrates for your business, come to speak to our specialist – maybe we can help.

  81.   Retweeted

    Thank you and for helping me meet a real life superhero. Ashanti DeSilva the first person in the world treated with 28 years ago. A passionate , advocate and a personal inspiration

  82.   Retweeted

    Wonderful to meet Baroness Fairhead CBE, Minister of State at DIT on the UK Pavilion at

  83.   Retweeted

    The expo floor is a trip around the world of innovation!

  84.   Retweeted

    Great reception at Startup Stadium today. It’s been a great week here in Boston.

  85.   Retweeted

    No rest for attendees! It’s the last day of Convention, but the action isn’t slowing down yet. Look out for these featured events in today’s schedule: